The efficacy and safety of benralizumab, an interleukin-5 receptor alpha–directed cytolytic monoclonal antibody, for the prevention of exacerbations in patients with moderate to very severe ...

Benralizumab is a humanized, afucosylated monoclonal antibody with high affinity and specificity for the human interleukin-5 receptor α subunit (interleukin-5Rα) expressed on eosinophils 14 and ...

Benralizumab is noninferior to mepolizumab in achieving remission of relapsing or refractory eosinophilic granulomatosis with polyangiitis at 36 and 48 weeks, according to data published in The ...

At both weeks 36 and 48, the benralizumab group exhibited an adjusted remission rate of 59.2%, while the mepolizumab group demonstrated a rate of 56.5% (difference, 2.71%; 95% CI, -12.54 to 17.96 ...

Benralizumab, an anti–interleukin-5 receptor alpha monoclonal antibody, was significantly better than placebo at producing a histologic response of up to six eosinophils per high-power field ...

Researchers conducted a real-world study to evaluate if long-term remission was viable among adult patients with SEA (mean age at the index date, 55.2 years; 58.7% women) who received benralizumab ...

Benralizumab induced histological remission at 12 weeks in more than three-fourths of patients with eosinophilic gastritis, although other biomarkers of disease persisted, according to data in The ...

Among 211 patients ages 12 to 65 years, 87.4% of those receiving benralizumab had a histologic response -- defined as at least six eosinophils per high-power field -- compared with 6.5% of ...

Recent research suggests that the biologic medications benralizumab and dupilumab can help treat emphysema. Learn more here.

The FDA expanded the approval of benralizumab (Fasenra) to include treatment of younger kids with uncontrolled severe asthma with an eosinophilic phenotype, AstraZeneca announced on Thursday ...

Find out how to take Benralizumab(drug) and its dose. Describes the best time to take the drug and precautions if any that should be followed.

Gastroenterology > General Gastroenterology Benralizumab Led to Histologic Responses in Eosinophilic Esophagitis — But there was no significant difference in symptom relief compared with placebo ...